Home / Health / Eli Lilly's Retatrutide Promises Unprecedented Weight Loss
Eli Lilly's Retatrutide Promises Unprecedented Weight Loss
21 May
Summary
- New drug retatrutide achieved up to 30% body weight loss in trials.
- Results rival bariatric surgery's effectiveness in weight reduction.
- Retatrutide mimics three hormones, potentially aiding GLP-1 non-responders.
Eli Lilly's experimental weight loss drug, retatrutide, has shown unprecedented results in recent clinical trials, with participants shedding up to 30% of their body weight. This significant achievement, averaging around 85 pounds for some, matches the efficacy of bariatric surgery.
The drug, a triple agonist mimicking GLP-1, GIP, and glucagon, is poised to be a game-changer in obesity treatment. Experts note its potential to help individuals with severe obesity or those unresponsive to current GLP-1 treatments.
Results from an 80-week phase 3 trial involving 2,300 patients indicated an average weight loss of 28% with the highest weekly dose. Lilly anticipates filing for FDA approval as early as this year.
Common side effects such as nausea and constipation were observed, similar to other GLP-1 drugs. Despite higher dropout rates than some competitors, retatrutide represents a significant advancement in the next generation of weight loss therapies.
